Learn About Alopecia Areata
Alopecia areata is a common disorder that causes hair loss. "Alopecia" is a Latin term that means baldness, and "areata" refers to the patchy nature of the hair loss that is typically seen with this condition.
The causes of alopecia areata are complex and not well understood. A combination of factors likely underlies the disorder, including changes in many genes that function in the hair and skin and in the immune system.
Alopecia areata affects 1 in every 500 to 1,000 people in the United States. It is one of many recognized forms of alopecia; alopecia areata is the second most common form after androgenetic alopecia (male-pattern baldness in men and female-pattern baldness in women). Alopecia areata affects men and women equally, and it can occur in people of any ethnic background.
The inheritance pattern of alopecia areata is unclear because multiple genetic and environmental factors appear to be involved. Overall, the risk of developing the condition is greater for first-degree relatives (such as siblings or children) of affected individuals than it is in the general population. People with alopecia areata are also more likely to have family members with other autoimmune disorders.
Cleveland Clinic Main Campus
Wilma Bergfeld is a Dermatologist in Cleveland, Ohio. Dr. Bergfeld has been practicing medicine for over 66 years and is rated as an Elite provider by MediFind in the treatment of Alopecia Areata. Her top areas of expertise are Autosomal Recessive Hypotrichosis, Graham-Little-Piccardi-Lassueur Syndrome, Alopecia Areata, Squamous Cell Skin Carcinoma, and Osteotomy.
David Norris is a Dermatologist in Aurora, Colorado. Dr. Norris is rated as an Elite provider by MediFind in the treatment of Alopecia Areata. His top areas of expertise are Alopecia Areata, Autosomal Recessive Hypotrichosis, Eosinophilic Fasciitis, and Female Pattern Baldness. Dr. Norris is currently accepting new patients.
Rodney Sinclair practices in Parkville, Australia. Mr. Sinclair is rated as an Elite expert by MediFind in the treatment of Alopecia Areata. His top areas of expertise are Autosomal Recessive Hypotrichosis, Alopecia Areata, Monilethrix, and Lichen Planus.
Summary: This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achieving Eczema Area and Severity Index (EASI) 75 response for AD, or SALT \<= 20 for AA) will be kept on t...
Summary: The main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 36-week Double-Blind Treatment Period, an approximately 2-year Long-term Extension Period, and a 4-week Post-treatment Fol...
Published Date: June 01, 2018
Published By: National Institutes of Health